Cannabis Science Inc (OTCMKTS:CBIS) is a micro-cap stock in the medical marijuana space that has been on a true roller coaster ride, with recent action turning back to the upside. The challenge here is reconciling some of the seeming managerial and capital mismanagement in the company’s past with some of the good news starting to come into the picture. As we noted in our last update, we have seen some recent positives emerge in the company after their visit to the Dana Farber/Harvard Cancer Center.
Dr. Wilfred F. Ngwa, Director of Global Health Catalyst at the center, stated, “I must say that we were pleasantly surprised with the depth of knowledge, clearly targeted missions, and direct plan of action delivered by Cannabis Science. It was certainly refreshing and clear. We invited Mr. Dabney and his team to discuss the drug development success and progress the company had made over the years. Partnerships between the CBIS team and scientists here at the DF/HCC are expected to bring a deeper understanding of the potential effectiveness of cannabinoids in the treatment of cancer and other chronic diseases. We will outline the critical motivations for our research partnership with a view of successfully publishing these in a high impact peer-reviewed medical journal.”
Cannabis Science Inc (OTCMKTS:CBIS) frames itself as a company that develops, produces, and commercializes phyto cannabinoid-based pharmaceutical products primarily in the United States. The company is involved in developing medicines for autism, blood pressure, cancer and cancer side effects, as well as for other illnesses comprising for general health maintenance. It also develops CS-TATI-1 for newly diagnosed and treatment-experienced patients with drug-resistant HIV strains, as well as those intolerant of available therapies; CS-S/BCC-1 to treat basal and squamous cell carcinomas; and a proprietary cannabis-based therapy for neurological conditions.
In addition, the company offers an online video-based medical cannabis education system, including courses, such as medical cannabis law, medical marijuana, cooking, horticulture, and bud tending; and manufactures and distributes specialty horse and pet grooming and topical applications. It has a license agreement with Apothecary Genetics Investments LLC to produce various brand formulations for California medical cannabis market.
Cannabis Science Inc also has collaboration with IGXBio, Inc. to develop GenePro, a DNA-based immunotherapeutic drug. Cannabis Science, Inc. is based in Colorado Springs, Colorado. Cannabis Science Inc is a subsidiary of Weedmaps Media, Inc.
Find out when $CBIS stock reaches critical levels. Subscribe to OracleDispatch.com Right Now by entering your Email in the box below.
According to company materials, “Cannabis Science, Inc., takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. Cannabinoids have an extensive history dating back thousands of years, and currently, there are a growing number of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate. The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness. Our initial focus is on skin cancers, HIV/AIDS, and neurological conditions. The Company is proceeding with the research and development of its proprietary drugs as a part of this initial focus: CS-S/BCC-1, CS-TATI-1, and CS-NEURO-1, respectively.”
In recent action, we’ve witnessed 5% piled on for shareholders of the company during the trailing week, and about 30% ramped on since the pivot lows in late November. The situation may be worth watching. CBIS has evidenced sudden upward volatility on many prior occasions.
What’s more, the stock has registered increased average transaction volume recently, with the past month seeing 28% above the average volume levels in play in this stock over the longer term.
At this time, carrying a capital value in the market of $96.9M, CBIS has very little cash on the books, along with total assets just under $1.1M, which must be weighed relative to an appreciable load ($2.41M) of total accumulated debt.
CBIS is not pre-revenue, with trailing 12-month revenues coming in at 48.60k. That said, a bet here is clearly a wagering on some qualitative emergence as the company begins to go to market with its newer R&D material. As more color becomes clear on the name, we will review the situation and update our take. For continuing coverage on shares of $CBIS stock, as well as our other hot stock picks, sign up for our free newsletter today and get our next hot stock pick!